mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03288350|
Recruitment Status : Recruiting
First Posted : September 20, 2017
Last Update Posted : March 22, 2018
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This is a single-center, single-arm, open-label, Simon 2-stage, phase II trial in up to 55 patients with a potentially resectable, histologically-proven, adenocarcinoma or poorly differentiated carcinoma of the stomach, esophagogastric junction (EGJ), or lower third of the esophagus.
Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5- fluorouracil. Following surgery, pathologic response will be assessed. Patients will then receive adjuvant therapy consisting of 4 cycles of mDCF + avelumab. Patients will be followed to assess two-year disease-free survival rates.
The primary objective of this study is to assess the effect on pathologic complete response rate (pCR) of adding avelumab to an mDCF regimen. The secondary objectives of this study are to determine the safety of adding avelumab to an mDCF regimen and assess its effect on two-year disease-free survival.
|Condition or disease||Intervention/treatment||Phase|
|Gastric Adenocarcinoma Esophageal Adenocarcinoma||Drug: mDCF + Avelumab||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||55 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Trial of Perioperative PD-L1 Inhibition With Avelumab and Docetaxel, Cisplatin and 5-Fluorouracil for Resectable Locally Advanced Esophago-Gastric Adenocarcinoma|
|Actual Study Start Date :||February 22, 2018|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||December 2023|
Experimental: mDCF + Avelumab
Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil, followed by surgery and assessment of pathologic response. Then they will receive 4 cycles of adjuvant therapy of docetaxel, cisplatin, 5-fluorouracil and avelumab.
Docetaxel as a one-hour 40 mg/m2 IV infusion on day 1. Cisplatin 40 mg/m2 IV infusion on day 1. 5-FU 1000 mg/m2/day over 2 days. Avelumab 10 mg/kg following the completion of the mDCF regimen.
Drug: mDCF + Avelumab
Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil (mDCF), followed by surgery and assessment of pathologic response. Then they will receive 4 cycles of adjuvant therapy of mDCF and avelumab.
- Pathologic Complete Response (pCR) [ Time Frame: 30±4 weeks ]Assessment of the pathologic complete response (pCR) rate after preoperative (neoadjuvant) treatment. pCR has been shown to correlate with long-term outcomes.For the purpose of this study, pCR is considered to represent grade 0 and grade 1 responses, defined by the criteria of the College of American Pathologists.
- Two-Year Disease Free Survival (DFS) [ Time Frame: 104 weeks ]Analysis of two-year disease-free survival (DFS) following treatment.
- Safety Assessment of Adding Avelumab to mDCF [ Time Frame: 104 weeks ]Measurement of the incidence of grade 3 or 4 avelumab-related adverse events following treatment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Signed, informed consent;
- Age 18 years or older;
- Histological diagnosis of adenocarcinoma or poorly differentiated carcinoma of the stomach, esophagogastric junction (EGJ), or lower third of the esophagus;
- The tumour must be deemed by the team to be potentially resectable. This includes imaging studies (detailed below) to clinically stage the tumor and rule out the presence of metastatic disease, and includes a preoperative laparoscopic evaluation for gastric tumors only;
- Stage IB (TlNl only), II, IHA, IIIB;
- Life expectancy greater than 3 months;
- ECOG performance status of 0-1;
- Neutrophils ~ 1500/μL;
- Platelet count~ 100,000/μL;
- Hemoglobin~ 9 g/dL;
- Total bilirubin level :S 1.5 x the upper limit of normal (ULN) range unless consistent with Gilbert's syndrome (normal direct bilirubin);
- AST and ALT :S 2.5 x ULN;
- If serum creatinine above upper limit of normal (ULN), creatinine clearance ~ 60 ml/min as determined by 24-h creatinine clearance or Cockcroft-Gault formula;
- Negative pregnancy test for women of child-bearing potential; and
- Highly effective contraception for both male and female subjects throughout the study and for at least 60 days after last avelumab treatment administration if the risk of conception exists.
Current or prior use of immunosuppressive medication, including corticosteroids, within 7 days prior to registration EXCEPT for the following:
- intranasal, intra-ocular, inhaled, topical steroids, or local steroid injection (e.g., intraarticular injection);
- Systemic corticosteroids at physiologic doses :S 10 mg/day of prednisone or equivalent;
- Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication);
- Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. However, patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible;
- Prior organ transplantation, including allogeneic stem cell transplantation;
- Squamous-cell carcinoma diagnosis;
Significant acute or chronic active infections requiring systemic therapy, including, among others:
- Known history of testing positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS);
- Positive test for HBV surface antigen and I or confirmatory HCV RNA (if anti-HCV antibody tested positive);
- Vaccination with live vaccines within 4 weeks of the first dose of avelumab and while on trial;
- Known severe hypersensitivity reactions to monoclonal antibodies (Grade 2: 3 NCI CTCAE v 4.03) or to any component in avelumab's formulation, any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma);
- Known severe hypersensitivity reaction to cisplatin, docetaxel, 5-FU or drugs formulated with polysorbate;
- Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction(< 6 months prior to enrollment), unstable angina, congestive heart failure (2: New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication;
- Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade> 1 ); however, alopecia, sensory neuropathy Grade :S 2, or other Grade :S 2 not constituting a safety risk based on investigator's judgment are acceptable;
- Other severe acute or chronic medical conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study;
- Known alcohol or drug abuse;
- Prior systemic therapy for gastric cancer;
- Prior exposure to antibodies directed at PD-1, PD-L 1, CTLA 4 antigens;
- Pre-existing medical conditions precluding treatment, including any contraindication for major surgery;
- Pregnancy or lactating mothers. Women of childbearing age must use contraception during and for 3 months following treatment;
- ECOG performance status of 2 or higher;
- Significant hearing impairment, as judged by the need for or use of a hearing aid. If there is any uncertainty regarding the degree of hearing impairment, an audiogram will be done. If the audiogram is grossly normal or shows only minor hearing impairment (i.e. not requiring hearing aid), the patient may be enrolled;
- Unwillingness to undergo investigations and/or treatment as outlined on the study; or
- Participation to another trial where an investigational drug is being used.
- History of another malignancy requiring treatment within the last 3 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin treated curatively and in-situ cervical cancer.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03288350
|Contact: Touhid Opu, MBBS, MSc||514-934-1934 ext email@example.com|
|McGill University Health Centre||Recruiting|
|Montréal, Quebec, Canada, H4A 3J1|
|Contact: Penny Chipman 514-934-1934 ext 64802 firstname.lastname@example.org|
|Principal Investigator: Thierry Alcindor, MD, MSc|
|Principal Investigator:||Thierry Alcindor, MD, MSc||Associate Director, Oncology Clinical Trials|
|Responsible Party:||Thierry Alcindor, Associate Director, Oncology Clinical Trials, McGill University Health Centre/Research Institute of the McGill University Health Centre|
|Other Study ID Numbers:||
|First Posted:||September 20, 2017 Key Record Dates|
|Last Update Posted:||March 22, 2018|
|Last Verified:||March 2018|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Phase II Trial
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents, Immunological